Froimson Mark
SEC Form 4 insider trading activity
Froimson Mark has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jun 13, 2026.
On the most recent filing, Froimson Mark is listed as Director at Pacira BioSciences, Inc. Inside the rolling window, Froimson Mark reported no open-market purchases and 1 open-market sale totaling $11K in PCRX.
Companies traded
Other insiders at PCRX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$11K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Froimson Mark made?
Froimson Mark has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Froimson Mark trade?
Froimson Mark has filed SEC Form 4 disclosures for 1 company, including PCRX.
When was Froimson Mark's most recent SEC Form 4 filing?
Froimson Mark's most recent SEC Form 4 filing on Tracefour is dated Jun 13, 2026.
What is Froimson Mark's total buy and sell value in the current window?
Inside the rolling retention window, Froimson Mark bought $0 and sold $11K based on SEC Form 4 filings.
What was Froimson Mark's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 500 PCRX shares on 2026-03-17, worth $11K, per SEC Form 4 filings.